161 related articles for article (PubMed ID: 10637920)
1. [Comments on the guidelines of the French-Language Society of Pneumology on the use of serum tumor markers in the management of primary bronchial cancers. Restatement].
Roche N; Lioté H; Housset B
Rev Mal Respir; 1999 Dec; 16(6):1165-6. PubMed ID: 10637920
[No Abstract] [Full Text] [Related]
2. [Are the ATS (American Thoracic Society) and the ERS (European Respiratory Society) correct in not recommending routine tumor marker assays foeening, staging, or evaluation of non-small cell lung cancer?].
Watine J; Charet JC
Rev Mal Respir; 1999 Apr; 16(2):139-49. PubMed ID: 10339757
[TBL] [Abstract][Full Text] [Related]
3. [Value of tumor markers for screening and diagnosis (except prognostic and surveillance values) in primary bronchial cancers].
Grivaux M
Rev Mal Respir; 1997 Apr; 14 Suppl 3():S15-9. PubMed ID: 9229742
[No Abstract] [Full Text] [Related]
4. [Which tumor markers should be used in primary bronchial cancers?].
Schuller MP; Carrat F; Urban T; Lebeau B
Rev Mal Respir; 1997 Apr; 14 Suppl 3():S9-14. PubMed ID: 9229750
[No Abstract] [Full Text] [Related]
5. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
6. [Value of tumor markers in surveillance of primary bronchial cancers and to evaluate therapy].
Sculier JP
Rev Mal Respir; 1997 Apr; 14 Suppl 3():S23-6. PubMed ID: 9229744
[No Abstract] [Full Text] [Related]
7. Prognostic markers for stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N
Lung Cancer; 2008 Feb; 59(2):274-5. PubMed ID: 18055061
[No Abstract] [Full Text] [Related]
8. [Usefulness of CYFRA21-1 as a tumor marker of non-small-cell lung cancer].
Tan Y; Zhang P; Zheng C
Zhonghua Zhong Liu Za Zhi; 1999 Jul; 21(4):287-9. PubMed ID: 11776818
[TBL] [Abstract][Full Text] [Related]
9. Invited commentary.
D'Amico T
Ann Thorac Surg; 2007 Jan; 83(1):221-2. PubMed ID: 17184667
[No Abstract] [Full Text] [Related]
10. [Recommendations concerning the use of serial tumor markers in management of primary bronchial cancers. Society of French Pneumology. Synthesis and recommendations].
Rev Mal Respir; 1997 Apr; 14 Suppl 3():S7-9. PubMed ID: 9229749
[No Abstract] [Full Text] [Related]
11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
12. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients.
Schneider J; Bitterlich N; Kotschy-Lang N; Raab W; Woitowitz HJ
Anticancer Res; 2007; 27(4A):1869-77. PubMed ID: 17649786
[TBL] [Abstract][Full Text] [Related]
13. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
14. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
Kasimir-Bauer S; Schleucher N; Weber R; Neumann R; Seeber S
Oncol Rep; 2003; 10(2):475-82. PubMed ID: 12579292
[TBL] [Abstract][Full Text] [Related]
16. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer].
Mroczko B; Szmitkowski M; Czygier M
Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186
[TBL] [Abstract][Full Text] [Related]
17. [Consensus conference. January 9 1992. Nice. Pretherapeutic evaluation of the extension of non small-cell bronchial carcinoma. French Language Society of Pneumology].
Rev Pneumol Clin; 1992; 48(1):35-40. PubMed ID: 1318572
[No Abstract] [Full Text] [Related]
18. [Value of serial tumor markers for determining the prognosis and predicting treatment response and survival].
Souquet PJ
Rev Mal Respir; 1997 Apr; 14 Suppl 3():S20-2. PubMed ID: 9229743
[No Abstract] [Full Text] [Related]
19. [CYFRA 21-1].
Pujol JL
Rev Mal Respir; 1997 Apr; 14 Suppl 3():S31-6. PubMed ID: 9229747
[No Abstract] [Full Text] [Related]
20. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
Muley T; Fetz TH; Dienemann H; Hoffmann H; Herth FJ; Meister M; Ebert W
Lung Cancer; 2008 Jun; 60(3):408-15. PubMed ID: 18083270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
